Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 3/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dyrene SCHEMBL8178116 | 0.90 | TSHR (0.75) | MAPTALDH1A1KMT2AKDM4ESMN1; SMN2 | |
| Dyrene SCHEMBL7191646 | 0.87 | MAPT (0.50) | MAPTALDH1A1KMT2AKDM4ESMN1; SMN2 | |
| Dyrene SCHEMBL5483770 | 0.87 | MAPT (0.50) | MAPTALDH1A1KMT2AKDM4ESMN1; SMN2 | |
| Dyrene SCHEMBL21854003 | 0.85 | TSHR (0.83) | MAPTALDH1A1KMT2AKDM4ESMN1; SMN2 | |
| Dyrene SCHEMBL5954767 | 0.84 | TSHR (0.86) | MAPTALDH1A1KMT2AKDM4ESMN1; SMN2 | |
| Dyrene SCHEMBL504140 | 0.83 | MAPT (0.46) | MAPTALDH1A1KMT2AKDM4ESMN1; SMN2 | |
| Dyrene SCHEMBL1029941 | 0.83 | MAPT (0.46) | MAPTALDH1A1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL29609022 | 0.82 | MAPT (0.93) | MAPTALDH1A1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL6237782 | 0.82 | MAPT (0.93) | MAPTALDH1A1KMT2AKDM4ESMN1; SMN2 | |
| Dyrene SCHEMBL690206 | 0.82 | TSHR (0.96) | MAPTALDH1A1KMT2AKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102159181-A | Cationic latex as a carrier for active ingredients and methods of making and using the same | MALLAR CREEK POLYMERS INC | 2011-08-17 | — | — | CN | claimed |
| EP-4216909-A1 | MOISTURIZING ANTIBACTERIAL COMPOSITION | Unilever IP Holdings B.V. (NL) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022063596-A1 | MOISTURIZING ANTIBACTERIAL COMPOSITION | UNILEVER IP HOLDINGS B.V. (NL) | 2022-03-31 | — | — | WO | disclosed |
| US-11207256-B2 | Method for solubilizing poorly water-soluble cosmetic agents | ATHENION AG (CH) | 2021-12-28 | — | — | US | disclosed |
| US-20200170915-A1 | METHOD FOR SOLUBILIZING POORLY WATER-SOLUBLE COSMETIC AGENTS | ATHENION AG (CH) | 2020-06-04 | — | — | US | disclosed |
| EP-3645125-A1 | METHOD FOR SOLUBILIZING POORLY WATER-SOLUBLE COSMETIC AGENTS | Athenion AG (CH) | 2020-05-06 | — | — | EP | disclosed |
| WO-2019001770-A1 | METHOD FOR SOLUBILIZING POORLY WATER-SOLUBLE COSMETIC AGENTS | ATHENION AG (CH) | 2019-01-03 | — | — | WO | disclosed |
| EP-3421096-A1 | METHOD FOR SOLUBILIZING POORLY WATER-SOLUBLE COSMETIC AGENTS | Athenion AG (CH) | 2019-01-02 | — | — | EP | disclosed |
| US-9333159-B2 | Topical DNA repair composition | PHOTOMEDEX, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20150118272-A1 | METHODS FOR ENHANCING COSMETIC OR DERMATOLOGICAL NOVEL COSMETIC OR DERMATOLOGICAL COMPOSITIONS CONTAINING A DIBENZOYL METHANE DERIVATIVE BY THE ADDITION OF MODIFIED TITANIUM DIOXIDE PARTICLES | DSM IP ASSETS B.V. (NL) | 2015-04-30 | — | — | US | disclosed |
| US-8278459-B2 | UV-filter compounds | DSM IP ASSETS B.V. (NL) | 2012-10-02 | — | — | US | disclosed |
| CN-102421809-A | Cationic comb copolymers, preparation thereof and use thereof in cosmetic, pharmaceutical and dermatological formulations | CLARIANT INT LTD | 2012-04-18 | — | — | CN | disclosed |
| EP-2274057-A1 | SUNSCREENS | DSM IP Assets B.V. (NL) | 2011-01-19 | — | — | EP | disclosed |
| CN-101903005-A | Cosmetic composition for imparting superhydrophobic film | AVON PROD INC | 2010-12-01 | — | — | CN | disclosed |
| US-20100119462-A1 | UV-FILTER COMPOUNDS | DSM IP ASSETS B.V. (NL) | 2010-05-13 | — | — | US | disclosed |
| WO-2009138485-A1 | SUNSCREENS | DSM IP ASSETS B.V. (NL) | 2009-11-19 | — | — | WO | disclosed |
| CN-101365412-A | Novel cosmetic or dermatological combinations comprising modified titanium dioxide particles | DSM IP ASSETS BV (NL) | 2009-02-11 | — | — | CN | disclosed |
| US-20090016986-A1 | Cosmetic Composition, a Pharmaceutical Composition and a Process for Preparing Said Compositions | NATURA COSMETICOS S.A. (BR) | 2009-01-15 | — | — | US | disclosed |
| US-20080305133-A1 | Novel Cosmetic or Dermatological Combinations Comprising Modified Titanium Dioxide Particles | DSM IP ASSETS B.V. (NL) | 2008-12-11 | — | — | US | disclosed |
| US-7037515-B2 | Anhydrous insect repellent composition | AVON PRODUCTS INC. (US) | 2006-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100119462-A1 | UV-FILTER COMPOUNDS | ERCC4, ERCC5, ERCC1 | MAPT 1798/4885ALDH1A1 189/4885KMT2A 2742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.